NDA 209637 · Novo
Ozempic
Semaglutide · Subcutaneous
NovelLast checked: Nov 20, 2026Latest source record: Aug 27, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2017
Dec 5, 2017
Approved uses
4
Original approval plus efficacy supplements
Registered trials
626
187 Phase 3, 161 recruiting
FAERS reports
70,721
35,100 serious, 1,193 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: RISK OF THYROID C-CELL TUMORS • In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether OZEMPIC causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined [see Warnings and Precautions ( 5.1 ), Nonclinical Toxicology ( 13.1 )] . • OZEMPIC is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [see Contraindications ( 4 )] . Counsel patients regarding the potential risk for MTC with the use of OZEMPIC and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid...
What it is approved for
From the label in effect Jul 30, 2026.
OZEMPIC is indicated: • as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. • to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease. • to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes mellitus and chronic kidney disease. OZEMPIC is a glucagon-like peptide 1 (GLP-1) receptor agonist indicated: • as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ( 1 ) • to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease. ( 1 ) • to reduce the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes mellitus and chronic kidney disease. ( 1 )
Mechanism: Semaglutide is a GLP-1 analogue with 94% sequence homology to human GLP-1. Semaglutide acts as a GLP-1 receptor agonist that selectively binds to and activates the GLP-1 receptor, the target for native GLP-1. GLP-1 is a physiological hormone that has multiple actions on glucose, mediated by the GLP-1 receptors. The principal mechanism of protraction resulting in the long half-life of semaglutide is albumin binding, which results in decreased renal clearance and protection from metabolic degradation. Furthermore, semaglutide is stabilized against degradation by the DPP-4 enzyme. Semaglutide...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jan 28, 2025 Supplement 25 · Efficacy LabelLetter
- Mar 28, 2022 Supplement 9 · Efficacy LetterLabel
- Jan 16, 2020 Supplement 3 · Efficacy LabelLetter
- Dec 5, 2017 Original approval · Type 1 - New Molecular Entity NovelLabelLetterReview
7 products under this application
- OZEMPIC · SEMAGLUTIDE 8MG/3ML (2.68MG/ML) · SOLUTION, SUBCUTANEOUS · Prescription
- OZEMPIC · SEMAGLUTIDE 2MG/1.5ML (1.34MG/ML) · SOLUTION, SUBCUTANEOUS · Discontinued
- OZEMPIC · SEMAGLUTIDE 0.5MG/0.5ML (0.5MG/0.5ML) · SOLUTION, SUBCUTANEOUS · Prescription
- OZEMPIC · SEMAGLUTIDE 2MG/3ML (0.68MG/ML) · SOLUTION, SUBCUTANEOUS · Prescription
- OZEMPIC · SEMAGLUTIDE 4MG/3ML (1.34MG/ML) · SOLUTION, SUBCUTANEOUS · Prescription
- OZEMPIC · SEMAGLUTIDE 1MG/0.5ML (1MG/0.5ML) · SOLUTION, SUBCUTANEOUS · Prescription
- OZEMPIC · SEMAGLUTIDE 0.25MG/0.5ML (0.25MG/0.5ML) · SOLUTION, SUBCUTANEOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Semaglutide" as an intervention, any sponsor and status, largest first.
- A Study of Cardiovascular Events iN Diabetes PlusPivotal-lookingActive, not recruiting
University of OxfordAcademic, hospital or other
NCT05441267 · 21,296 participants · Start Mar 13, 2023 · Primary completion Aug 17, 2028
Drug: Semaglutide Oral Tablet; Placebo oral tablet · For: Diabetes Mellitus, Type 2
Sites: Oxford, United Kingdom
- Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or ObesityPivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT03574597 · 17,604 participants · Start Oct 24, 2018 · Primary completion Jun 21, 2023
Drug: Semaglutide; Placebo (semaglutide) · For: Overweight; Obesity
Sites: Birmingham, Alabama; Montgomery, Alabama; Glendale, Arizona · 833 sites in all
- A Heart Disease Study of Semaglutide in Patients With Type 2 DiabetesPivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT03914326 · 9,651 participants · Start Jun 17, 2019 · Primary completion Aug 23, 2024
Drug: Semaglutide; Placebo (semaglutide) · For: Diabetes Mellitus, Type 2
Sites: Montgomery, Alabama; Little Rock, Arkansas; Searcy, Arkansas · 492 sites in all
- REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood VesselsPivotal-lookingActive, not recruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT05669755 · 7,101 participants · Start Mar 1, 2023 · Primary completion Sep 1, 2027
Drug: Cagrilintide; Semaglutide and 1 more · For: Cardiovascular Disease
Sites: Birmingham, Alabama; Montgomery, Alabama; Scottsdale, Arizona · 633 sites in all
- PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 DiabetesPivotal-lookingRecruiting
Brigham and Women's HospitalAcademic, hospital or other
NCT05390892 · 6,000 participants (planned) · Start Sep 26, 2022 · Primary completion Mar 1, 2029
Drug: SGLT2 inhibitor; GLP-1 receptor agonist · For: Type2Diabetes; ASCVD
Sites: Huntsville, Alabama; Scottsdale, Arizona; Los Angeles, California · 36 sites in all
- A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney DiseasePivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT03819153 · 3,533 participants · Start Jun 17, 2019 · Primary completion Jan 9, 2024
Drug: Semaglutide; Placebo (semaglutide) · For: Diabetes Mellitus, Type 2
Sites: Tuscumbia, Alabama; Chula Vista, California; Concord, California · 413 sites in all
- A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose WeightPivotal-lookingActive, not recruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT05567796 · 3,400 participants (planned) · Start Nov 1, 2022 · Primary completion Oct 30, 2024
Drug: Cagrilintide; Semaglutide and 2 more · For: Obesity
Sites: Birmingham, Alabama; Los Angeles, California; Aurora, Colorado · 256 sites in all
- Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 DiabetesPivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT01720446 · 3,297 participants · Start Feb 21, 2013 · Primary completion Mar 15, 2016
Drug: semaglutide; semaglutide and 1 more · For: Diabetes; Diabetes Mellitus, Type 2
Sites: Birmingham, Alabama; Chandler, Arizona; Anaheim, California · 253 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- nausea10,175
- off label use7,482
- vomiting6,675
- diarrhoea6,326
- decreased appetite4,685
- constipation4,636
- weight decreased4,425
- impaired gastric emptying4,024
- product use in unapproved indication3,555
- blood glucose increased3,101
- wrong technique in product usage process3,008
- abdominal pain upper2,957
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2013 | 2 |
| 2014 | 3 |
| 2015 | 7 |
| 2016 | 12 |
| 2017 | 13 |
| 2018 | 1,140 |
| 2019 | 1,589 |
| 2020 | 3,032 |
| 2021 | 3,730 |
| 2022 | 5,301 |
| 2023 | 8,478 |
| 2024 | 12,875 |
| 2025 | 18,612 |
| 2026 | 15,927 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Ozempic (Semaglutide)
2024 spending
$13.0B
Beneficiaries
1,952,637
10,417,182 claims
Per beneficiary
$6,642
$306.48 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $1,455,812,267 |
| 2021 | $2,621,694,348 |
| 2022 | $4,628,160,643 |
| 2023 | $9,194,048,435 |
| 2024 | $12,970,296,347 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity.
Wharton S, Lingvay I, Bogdanski P, et al. · N Engl J Med 2025 · Clinical Trial, Phase II, Multicenter Study
- Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.
Aronne LJ, Horn DB, le Roux CW, et al. · N Engl J Med 2025 · Clinical Trial, Phase III, Comparative Study
- Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.
Davies M, Færch L, Jeppesen OK, et al. · Lancet 2021 · Clinical Trial, Phase III, Multicenter Study
- Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial.
Pratley RE, Aroda VR, Lingvay I, et al. · Lancet Diabetes Endocrinol 2018 · Clinical Trial, Phase III, Comparative Study
- Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis.
Yao H, Zhang A, Li D, et al. · BMJ 2024 · Systematic Review, Network Meta-Analysis
- Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial.
Ryan DH, Lingvay I, Deanfield J, et al. · Nat Med 2024 · Randomized Controlled Trial, Multicenter Study
Sponsor: Novo
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.